Log In
Print
BCIQ
Print
Print this Print this
 

oxycodone/acetaminophen (Xartemis XR) (COV795) (formerly MNK-795)

  Manage Alerts
Collapse Summary General Information
Company Mallinckrodt plc
DescriptionControlled-release oral formulation of oxycodone and acetaminophen formulated using Depomed's AcuForm gastric retentive formulation technology
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentApproved
Standard IndicationPain
Indication DetailsManage moderate to severe acute pain where the use of an opioid analgesic is appropriate
Regulatory Designation U.S. - Priority Review (Manage moderate to severe acute pain where the use of an opioid analgesic is appropriate)
Partner Depomed Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,800.0M

$1,800.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today